These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21969501)

  • 1. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.
    Chibaudel B; Bonnetain F; Shi Q; Buyse M; Tournigand C; Sargent DJ; Allegra CJ; Goldberg RM; de Gramont A
    J Clin Oncol; 2011 Nov; 29(31):4199-204. PubMed ID: 21969501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
    Chibaudel B; Maindrault-Goebel F; Lledo G; Mineur L; André T; Bennamoun M; Mabro M; Artru P; Carola E; Flesch M; Dupuis O; Colin P; Larsen AK; Afchain P; Tournigand C; Louvet C; de Gramont A
    J Clin Oncol; 2009 Dec; 27(34):5727-33. PubMed ID: 19786657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
    Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
    J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
    J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
    Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J
    J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression-free survival is a surrogate for survival in advanced colorectal cancer.
    Buyse M; Burzykowski T; Carroll K; Michiels S; Sargent DJ; Miller LL; Elfring GL; Pignon JP; Piedbois P
    J Clin Oncol; 2007 Nov; 25(33):5218-24. PubMed ID: 18024867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
    Masi G; Vasile E; Loupakis F; Cupini S; Fornaro L; Baldi G; Salvatore L; Cremolini C; Stasi I; Brunetti I; Fabbri MA; Puglisi M; Trenta P; Granetto C; Chiara S; Fioretto L; Allegrini G; Crinò L; Andreuccetti M; Falcone A
    J Natl Cancer Inst; 2011 Jan; 103(1):21-30. PubMed ID: 21123833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
    Allegra C; George T; Yothers G
    J Natl Cancer Inst; 2011 Jan; 103(1):4-5. PubMed ID: 21123834
    [No Abstract]   [Full Text] [Related]  

  • 13. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
    Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of sequential chemotherapy in the treatment of metastatic colorectal cancer].
    Tassinari D; Tamburini E; Carloni F; Nicoletti S; Ravaioli A
    Recenti Prog Med; 2009 Feb; 100(2):73-9. PubMed ID: 19350798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
    de Gramont A; Buyse M; Abrahantes JC; Burzykowski T; Quinaux E; Cervantes A; Figer A; Lledo G; Flesch M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; Tournigand C
    J Clin Oncol; 2007 Aug; 25(22):3224-9. PubMed ID: 17664470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.
    Seligmann JF; Fisher D; Smith CG; Richman SD; Elliott F; Brown S; Adams R; Maughan T; Quirke P; Cheadle J; Seymour M; Middleton G
    Ann Oncol; 2017 Mar; 28(3):562-568. PubMed ID: 27993800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
    Bonnetain F; Bosset JF; Gerard JP; Calais G; Conroy T; Mineur L; Bouché O; Maingon P; Chapet O; Radosevic-Jelic L; Methy N; Collette L
    Eur J Cancer; 2012 Aug; 48(12):1781-90. PubMed ID: 22507892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
    Sharma MR; Gray E; Goldberg RM; Sargent DJ; Karrison TG
    J Clin Oncol; 2015 Jan; 33(1):36-41. PubMed ID: 25349295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.
    Giessen C; Laubender RP; Ankerst DP; Stintzing S; Modest DP; Mansmann U; Heinemann V
    Clin Cancer Res; 2013 Jan; 19(1):225-35. PubMed ID: 23149819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.
    Sidhu R; Rong A; Dahlberg S
    Clin Cancer Res; 2013 Mar; 19(5):969-76. PubMed ID: 23303214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.